Baird raised the firm’s price target on Doximity (DOCS) to $80 from $75 and keeps an Outperform rating on the shares. The firm updated its model after attending Baird’s Global Healthcare Conference.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity could be impacted by FDA ad crackdown, says Raymond James
- Doximity Holds Annual Stockholders Meeting, Elects Directors
- Doximity Announces Leadership Change with New Appointments
- Doximity’s Strong Market Position and AI-Driven Growth Reinforce Buy Rating
- Doximity’s Earnings Call Highlights Growth and AI Advances